178 related articles for article (PubMed ID: 27567858)
1. ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies.
Boehm-Cagan A; Bar R; Liraz O; Bielicki JK; Johansson JO; Michaelson DM
J Alzheimers Dis; 2016 Oct; 54(3):1219-1233. PubMed ID: 27567858
[TBL] [Abstract][Full Text] [Related]
2. Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.
Boehm-Cagan A; Michaelson DM
J Neurosci; 2014 May; 34(21):7293-301. PubMed ID: 24849361
[TBL] [Abstract][Full Text] [Related]
3. ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes.
Rawat V; Wang S; Sima J; Bar R; Liraz O; Gundimeda U; Parekh T; Chan J; Johansson JO; Tang C; Chui HC; Harrington MG; Michaelson DM; Yassine HN
J Neurosci; 2019 Nov; 39(48):9611-9622. PubMed ID: 31641056
[TBL] [Abstract][Full Text] [Related]
4. Differential Effects of apoE4 and Activation of ABCA1 on Brain and Plasma Lipoproteins.
Boehm-Cagan A; Bar R; Harats D; Shaish A; Levkovitz H; Bielicki JK; Johansson JO; Michaelson DM
PLoS One; 2016; 11(11):e0166195. PubMed ID: 27824936
[TBL] [Abstract][Full Text] [Related]
5. Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice.
Carter AY; Letronne F; Fitz NF; Mounier A; Wolfe CM; Nam KN; Reeves VL; Kamboh H; Lefterov I; Koldamova R
PLoS One; 2017; 12(2):e0172161. PubMed ID: 28241068
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.
Tai LM; Koster KP; Luo J; Lee SH; Wang YT; Collins NC; Ben Aissa M; Thatcher GRJ; LaDu MJ
J Biol Chem; 2014 Oct; 289(44):30538-30555. PubMed ID: 25217640
[TBL] [Abstract][Full Text] [Related]
7. Reversal of ApoE4-Driven Brain Pathology by Vascular Endothelial Growth Factor Treatment.
Salomon-Zimri S; Glat MJ; Barhum Y; Luz I; Boehm-Cagan A; Liraz O; Ben-Zur T; Offen D; Michaelson DM
J Alzheimers Dis; 2016 Jun; 53(4):1443-58. PubMed ID: 27372644
[TBL] [Abstract][Full Text] [Related]
8. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice.
Fitz NF; Cronican AA; Saleem M; Fauq AH; Chapman R; Lefterov I; Koldamova R
J Neurosci; 2012 Sep; 32(38):13125-36. PubMed ID: 22993429
[TBL] [Abstract][Full Text] [Related]
9. A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3.
Valencia-Olvera AC; Balu D; Bellur S; McNally T; Saleh Y; Pham D; Ghura S; York J; Johansson JO; LaDu MJ; Tai L
Alzheimers Res Ther; 2023 Dec; 15(1):216. PubMed ID: 38102668
[TBL] [Abstract][Full Text] [Related]
10. ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice.
Liraz O; Boehm-Cagan A; Michaelson DM
Mol Neurodegener; 2013 May; 8():16. PubMed ID: 23684315
[TBL] [Abstract][Full Text] [Related]
11. An Anti-apoE4 Specific Monoclonal Antibody Counteracts the Pathological Effects of apoE4 In Vivo.
Luz I; Liraz O; Michaelson DM
Curr Alzheimer Res; 2016 Jun; 13(8):918-29. PubMed ID: 27040139
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway.
Zhao J; Fu Y; Liu CC; Shinohara M; Nielsen HM; Dong Q; Kanekiyo T; Bu G
J Biol Chem; 2014 Apr; 289(16):11282-11292. PubMed ID: 24599963
[TBL] [Abstract][Full Text] [Related]
13. Opposing effects of Apoe/Apoa1 double deletion on amyloid-β pathology and cognitive performance in APP mice.
Fitz NF; Tapias V; Cronican AA; Castranio EL; Saleem M; Carter AY; Lefterova M; Lefterov I; Koldamova R
Brain; 2015 Dec; 138(Pt 12):3699-715. PubMed ID: 26510953
[TBL] [Abstract][Full Text] [Related]
14. 5-HT3 Antagonist Ondansetron Increases apoE Secretion by Modulating the LXR-ABCA1 Pathway.
Shinohara M; Shinohara M; Zhao J; Fu Y; Liu CC; Kanekiyo T; Bu G
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30934555
[TBL] [Abstract][Full Text] [Related]
15. Extra-Hippocampal Learning Deficits in Young Apolipoprotein E4 Mice and Their Synaptic Underpinning.
Har-Paz I; Roisman N; Michaelson DM; Moran A
J Alzheimers Dis; 2019; 72(1):71-82. PubMed ID: 31561365
[TBL] [Abstract][Full Text] [Related]
16. ABCA1 haplodeficiency affects the brain transcriptome following traumatic brain injury in mice expressing human APOE isoforms.
Castranio EL; Wolfe CM; Nam KN; Letronne F; Fitz NF; Lefterov I; Koldamova R
Acta Neuropathol Commun; 2018 Jul; 6(1):69. PubMed ID: 30049279
[TBL] [Abstract][Full Text] [Related]
17. Absence of ApoE upregulates murine brain ApoD and ABCA1 levels, but does not affect brain sterol levels, while human ApoE3 and human ApoE4 upregulate brain cholesterol precursor levels.
Jansen PJ; Lütjohann D; Thelen KM; von Bergmann K; van Leuven F; Ramaekers FC; Monique M
J Alzheimers Dis; 2009; 18(2):319-29. PubMed ID: 19584433
[TBL] [Abstract][Full Text] [Related]
18. Intraneuronal amyloid-beta plays a role in mediating the synergistic pathological effects of apoE4 and environmental stimulation.
Levi O; Dolev I; Belinson H; Michaelson DM
J Neurochem; 2007 Nov; 103(3):1031-40. PubMed ID: 17666042
[TBL] [Abstract][Full Text] [Related]
19. The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo.
Salomon-Zimri S; Koren A; Angel A; Ben-Zur T; Offen D; Michaelson DM
Curr Alzheimer Res; 2019; 16(4):281-292. PubMed ID: 30819082
[TBL] [Abstract][Full Text] [Related]
20. The effects of apolipoprotein E genotype, α-synuclein deficiency, and sex on brain synaptic and Alzheimer's disease-related pathology.
Bar R; Boehm-Cagan A; Luz I; Kleper-Wall Y; Michaelson DM
Alzheimers Dement (Amst); 2018; 10():1-11. PubMed ID: 29159264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
